FHTX Q3 2022 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+16080.5% YoY

Gross Profit

-$20M-305.9% margin

Operating Income

-$28M-426.0% margin

Net Income

-$26M-388.4% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+47.8%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$434M

Total Liabilities

$410M

Stockholders' Equity

$24M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$41,000	+16080.5%
Gross Profit	-$20M	-$20M	+0.8%
Operating Income	-$28M	-$26M	-7.6%
Net Income	-$26M	-$26M	+1.2%